Australian tertiary care outcomes of entecavir monotherapy in treatment naive patients with chronic hepatitis B

about

Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil.Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir.

P2860

Q36793870-6F7D5A13-3804-4CB4-89BF-E495B7EB0324 Q38223361-C7B28385-2993-48D6-9A17-42B691DB0A88

P2860

Australian tertiary care outcomes of entecavir monotherapy in treatment naive patients with chronic hepatitis B

Item

http://www.wikidata.org/entity/Q36615961

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Australian tertiary care outco ...... ients with chronic hepatitis B

@ast

Australian tertiary care outco ...... ients with chronic hepatitis B

@en

type

Item

label

Australian tertiary care outco ...... ients with chronic hepatitis B

@ast

Australian tertiary care outco ...... ients with chronic hepatitis B

@en

prefLabel

Australian tertiary care outco ...... ients with chronic hepatitis B

@ast

Australian tertiary care outco ...... ients with chronic hepatitis B

@en

P1476

Australian tertiary care outco ...... ients with chronic hepatitis B

@en

P2093

Farzan Fahrtash-Bahin

http://www.w3.org/2001/XMLSchema#string

Jacob George

http://www.w3.org/2001/XMLSchema#string

Karen Byth

http://www.w3.org/2001/XMLSchema#string

Mark W Douglas

http://www.w3.org/2001/XMLSchema#string

Timothy Gray

http://www.w3.org/2001/XMLSchema#string

Viraj C Kariyawasam

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus

Australia's notifiable disease status, 2010: annual report of the National Notifiable Diseases Surveillance System.

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management.

Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach.

First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice

Virological, serological and biochemical outcomes through 3 years of entecavir treatment in nucleoside-naive Chinese chronic hepatitis B patients.

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

P304

721-726

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V19.I5.721

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235690882

http://www.w3.org/2001/XMLSchema#string

P698

23430314

http://www.w3.org/2001/XMLSchema#string

P932

3574598

http://www.w3.org/2001/XMLSchema#string

Australian tertiary care outcomes of entecavir monotherapy in treatment naive patients with chronic hepatitis B

about

P2860

P2860

Australian tertiary care outcomes of entecavir monotherapy in treatment naive patients with chronic hepatitis B

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932